ERK inhibitors as a potential new therapy for rheumatoid arthritis

Drug News and Perspectives

Volumn 21, Issue 5, 2008, Pages 245-250

  Ohori, Makoto ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 ALLYL 5 (2 PHENYLPYRAZOLO[1,5 A]PYRIDIN 3 YL) 1H PYRAZOLO[3,4 C]PYRIDAZIN 3 AMINE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 5 IODOTUBERCIDIN; ANTIRHEUMATIC AGENT; FR 148083; FR 180204; LL Z1640 2; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PYRIDAZINE DERIVATIVE; PYRROLE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANTIGEN SPECIFICITY; ARTICLE; AUTOIMMUNE DISEASE; CHRONIC DISEASE; CRYSTAL STRUCTURE; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; FIBROBLAST; HUMAN; JOINT DESTRUCTION; MACROPHAGE; NONHUMAN; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYNOVIOCYTE; SYSTEMIC DISEASE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; IMMUNOLOGIC FACTORS; MICE;

EID: 51549098356     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/DNP.2008.21.5.1219006     Document Type: Article

References (35)

1. MacKenzie, N.M. New therapeutics that treat rheumatoid arthritis by blocking T-cell activation. Drug Discov Today 2006, 11(19-20): 952-6.
2. Goldblatt, F. and Isenberg, D.A. New therapies for rheumatoid arthritis. Clin Exp Immunol 2005, 140(2): 195-204.
3. Schett, G., Tohidast-Akrad, M., Smolen, J.S. et al. Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis. Arthritis Rheum 2000, 43(11): 2501-12.
4. Cope, A.P. Studies of T-cell activation in chronic inflammation. Arthritis Res 2002, 3(4 Suppl.): S197-211.
5. Pap, T., Nawrath, M., Heinrich, J. et al. Cooperation of Ras- and c-Myc-dependent pathways in regulating the growth and invasiveness of synovial fibroblasts in rheumatoid arthritis. Arthritis Rheum 2004, 50(9): 2794-802.
6. Gemba, T., Valbracht, J., Alsalameh, S. and Lotz, M. Focal adhesion kinase and mitogen-activated protein kinases are involved in chondrocyte activation by the 29-kDa amino-terminal fibronectin fragment. J Biol Chem 2002, 277(2): 907-11.
7. Hoberg, M., Rudert, M., Pap, T., Klein, G., Gay, S. and Aicher, W.K. Attachment to laminin-111 facilitates transforming growth factor beta-induced expression of matrix metalloproteinase-3 in synovial fibroblasts. Ann Rheum Dis 2007, 66(4): 446-51.
8. Lacey, D., Sampey, A., Mitchell, R., Bucala, R., Santos, L., Leech, M. and Morand, E. Control of fibroblast-like synoviocyte proliferation by macrophage migration inhibitory factor. Arthritis Rheum 2003, 48(1): 103-9.
9. Tanaka, S. Intracellular signal transduction pathways: Good therapeutic targets for joint destruction in rheumatoid arthritis. Mod Rheumatol 2005, 15(1): 19-27.
10. Kunisch, E., Gandesiri, M., Fuhrmann, R., Roth, A., Winter, R. and Kinne, R.W. Predominant activation of MAP kinases and pro-destructive/ pro-inflammatory features by TNF alpha in early-passage synovial fibroblasts via TNF receptor-1: Failure of p38 inhibition to suppress matrix metalloproteinase-1 in rheumatoid arthritis. Ann Rheum Dis 2007, 66(8): 1043-51.
11. Gortz, B., Hayer, S., Tuerck, B., Zwerina, J., Smolen, J.S. and Schett, G. Tumour necrosis factor activates the mitogen-activated protein kinases p38alpha and ERK in the synovial membrane in vivo. Arthritis Res Ther 2005, 7(5): R1140-7.
12. Gao, B., Calhoun, K. and Fang D. The proinflammatory cytokines IL-1beta and TNF-alpha induce the expression of Synoviolin, an E3 ubiquilin ligase, in mouse synovial fibroblasts via the Erk1/2-ETS1 pathway. Arthritis Res Ther 2006, 8(6): R172.
13. Hall, J.P., Kurdi, Y., Hsu, S. et al. Pharmacologic inhibition of tpl2 blocks inflammatory responses in primary human monocytes, synoviocytes, and blood. J Biol Chem 2007, 282(46): 33295-304.
14. Gilbert, S.J., Blain, E.J., Duance, V.C. and Mason, D.J. Sphingomyelinase decreases type II collagen expression in bovine articular cartilage chondrocytes via the ERK signaling pathway. Arthritis Rheum 2008, 58(1): 209-20.
15. Cruz, C.D., Neto, F.L., Castro-Lopes, J., McMahon, S.B. and Cruz, F. Inhibition of ERK phosphorylation decreases nociceptive behaviour in monoarthritic rats. Pain 2005, 116(3): 411-9.
16. Seino, D., Tokunaga, A., Tachibana, T. et al. The role of ERK signaling and the P2X receptor on mechanical pain evoked by movement of inflamed knee joint. Pain 2006, 123(1-2): 193-203.
17. Allam, A. and Marshall, A.J. Role of the adaptor proteins Bam32, TAPP1 and TAPP2 in lymphocyte activation. Immunol Lett 2005, 97(1): 7-17.
18. Dye, J.R., Palvanov, A., Guo, B. and Rothstein, T.L. B cell receptor cross-talk: Exposure to lipopolysaccharide induces an alternate pathway for B cell receptor-induced ERK phosphorylation and NF-kappa B activation. J Immunol 2007, 179(1): 229-35.
19. Eliopoulos, A.G., Wang, C.C., Dumitru, C.D. and Tsichlis, P.N. Tpl2 transduces CD40 and TNF signals that activate ERK and regulates IgE induction by CD40. EMBO J 2003, 22(15): 3855-64.
20. Ohori, M., Kinoshita, T., Okubo, M. et al. Identification of a selective ERK inhibitor and structural determination of the inhibitor-ERK2 complex. Biochem Biophys Res Commun 2005, 336(1): 357-63.
21. Kinoshita, T., Warizaya, M., Ohori, M., Sato, K., Neya, M. and Fujii, T. Crystal structure of human ERK2 complexed with a pyrazolo[3,4-c]pyridazine derivative. Bioorg Med Chem Lett 2006, 16(1): 55-8.
22. Hancock, C.N., Macias, A., Lee, E.K., Yu, S.Y., Mackerell, A.D. Jr. and Shapiro, P. Identification of novel extracellular signal-regulated kinase docking domain inhibitors. J Med Chem 2005, 48(14): 4586-95.
23. Chen, F., Hancock, C.N., Macias, A.T. et al. Characterization of ATP-independent ERK inhibitors identified through in silico analysis of the active ERK2 structure. Bioorg Med Chem Lett 2006, 16(24): 6281-7.
24. Aronov, A.M., Baker, C., Bemis, G.W. et al. Flipped out: Structure-guided design of selective pyrazolylpyrrole ERK inhibitors. J Med Chem 2007, 50(6): 1280-7.
25. Fox, T., Coll, J.T., Xie, X. et al. A single amino acid substitution makes ERK2 susceptible to pyridinyl imidazole inhibitors of p38 MAP kinase. Protein Sci 1998, 7(11): 2249-55.
26. Parkinson, F.E. and Geiger, J.D. Effects of iodotubercidin on adenosine kinase activity and nucleoside transport in DDT1 MF-2 smooth muscle cells. J Pharmacol Exp Ther 1996, 277(3): 1397-401.
27. Massillon, D., Stalmans, W, van de Werve, G. and Bollen, M. Identification of the glycogenic compound 5-iodotubercidin as a general protein kinase inhibitor. Biochem J 1994, 299(Pt. 1): 123-8.
28. Cottam, H.B., Wasson, D.B., Shih, H.C Raychaudhuri, A., Di Pasquale, G. and Carson, D.A. New adenosine kinase inhibitors with oral antiinflammatory activity: Synthesis and biological evaluation. J Med Chem 1993, 36(22): 3424-30.
29. Newby, A.C., Holmquist, C.A., Illingworth, J. and Pearson, J.D. The control of adenosine concentration in polymorphonuclear leucocytes, cultured heart cells and isolated perfused heart from the rat. Biochem J 1983, 214(2): 317-23.
30. Ohori, M., Kinoshita, T., Yoshimura, S., Warizaya, M., Nakajima, H. and Miyake, H. Role of a cysteine residue in the active site of ERK and the MAPKK family. Biochem Biophys Res Commun 2007, 353(3): 633-7.
31. Ohori, M., Takeuchi, M., Maruki, R., Nakajima, H. and Miyake, H. FR180204, a novel and selective inhibitor of extracellular signal-regulated kinase, ameliorates collagen-induced arthritis in mice. Naunyn Schmiedebergs Arch Pharmacol 2007, 374(4): 311-6.
32. Myers, L.K., Rosioniec, E.F., Cremer, M.A. and Kang, A.H. Collagen-induced arthritis, an animal model of autoimmunity. Life Sci 1997, 61(19): 1861-78.
33. Thiel, M.J., Schaefer, C.J., Lesch, M.E. et al. Central role of the MEK/ERK MAP kinase pathway in a mouse model of rheumatoid arthritis: Potential proinflammatory mechanisms. Arthritis Rheum 2007, 56(10): 3347-57.
34. Sebolt-Leopold, J.S., Dudley, D.T., Herrera, R. et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med 1999, 5(7): 810-6.
35. Mazanetz, M.P. and Fischer, P.M. Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. Nat Rev Drug Discov 2007, 6(6): 464-79.